Pharming Group N.V. and it’s Seoul based South Korean specialty pharma partner Hyupjin have received the marketing authorization for Ruconest in South Korea. Ruconest is approved for the treatment of acute angioedema attacks in adult patients with HAE. Effectiveness was not established in HAE patients with laryngeal and oro-pharyngeal attacks. HyupJin will now seek reimbursement for Ruconest in South Korea.
Sijmen de Vries, CEO of Pharming, commented: “HyupJin is a well-established and experienced company with a proven track record in South Korea. We look forward to them now extending the commercialisation of Ruconest by providing HAE patients in South Korea with a new, safe and effective treatment to treat their HAE atttacks.”
Choon Duk Kim, General Manager of Hyupjin Corporation, said: “Ruconest is the first approved recombinant C1 esterase inhibitor worldwide and this approval of Ruconest will now enable us to provide the Korean HAE patients access to this most innovative way to treat their disease. We fully appreciate all the supports from Pharming Group for the approval of Ruconest in South Korea and we look forward to getting started.”
Headquartered in Seoul, Korea, Hyupjin Corporation develops and distributes healthcare products from prominent companies in the USA and Europe since 1975. With 30 years of experience in the medical market, Hyupjin Corporation has tight relationships with healthcare professionals and has built extensive know-how of the medical community. Hyupjin’s product portfolio mainly consists of oncology and immunology products, but also OTCs, dietary supplements and medical devices. Hyupjin has made a consistent effort for the treatment of incurable diseases along with improvement of patient’s quality of life.
(Source: Pharming)
